Stock 9966 ALPHAMAB ONCOLOGY
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
4.67 HKD +4.94% Intraday chart for Alphamab Oncology +14.74% -29.67%
04-10 Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting MT
04-10 Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting
Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr
Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting
Alphamab Oncology Unit Renews Service Provision Contract, Annual Limits
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Suzhou Alphamab Co., Ltd. Announces Renewal of the Lease Agreement
Alphamab Oncology Reports Earnings Results for the Full Year Ended December 31, 2023
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033
Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine
Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable
Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor
Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer
Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE
Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO
Alphamab Oncology's H1 Loss Narrows on Surge in Revenue
Alphamab Oncology Reports Earnings Results for the Half Year Ended June 30, 2023
Alphamab Oncology Announces Research Updates on KN046 and KN026 for Presentation At ESMO Congress 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9966 Stock
  4. News Alphamab Oncology
  5. Other languages